Focus: AJ Vaccines is a Copenhagen-based biotech specializing in vaccine development, focused on infectious disease indications with adjuvanted and reduced-dose formulations. Founded in 2017, the company operates at a pre-commercial or early-commercial stage with a lean structure.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Early-stage vaccine specialist with promising pipeline catalysts, but limited hiring velocity and opaque financials make this a higher-risk, mission-driven opportunity best suited for scientists prioritizing therapeutic focus over job security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AJ Vaccines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AJ Vaccines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles